Cancer malignancy
Conditions
Interventions
None listed
Sponsors
Philips Research
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Patients with proven malignant lesion of breast, lung or liver or benign fibroadenoma of the breast 2. In case of breast malignancy; patients are scheduled for total or partial resection of the breast 3. In case of lung malignancy; patients are scheduled for local resection, lobectomy or pneumonectomy during an *open* thoracic procedure 4. In case of liver malignancy; patients are scheduled for local resection or hemi-hepatectomy 5. Patients undergoing RFA for colorectal liver metastases and in whom the RFA-needle trjact will be entirely ablated 6. Written informed consent 7. Patients >= 18 years old
Exclusion criteria
Exclusion criteria: 1. Patients with no proof of residual malignant disease after neo-adjuvant therapy by follow-up radiological analysis before operation 2. Patients with suspected sensitivity to light; e.g. patients who have had photodynamic therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Several optical spectroscopy parameters of the targeted tissues will be analysed, specified and then compared to histopathological analysis: 1. Diffuse reflectance parameters: Oxyhaemoglobin saturation, total haemoglobin content, water and fat content within the tissue as well as 2 scatter coefficients of the tissue. 2. Fluorescence parameters: Collagen, elastin, NADH content within the tissue. 3. Pathology parameters: histology characteristics of the tissue, tumor grade, percentage necrosis The analysis of the optical spectroscopy parameters will result in a specific tissue fingerprint allowing optical tissue characterization, discriminating malignant tissue from normal or benign tissue. These results will be compared to standard histopathological examination. Primary endpoint: To confirm that the locations where the optical spectroscopy spectra have been collected correspond to the confirmation images by ultrasound and definite results from pathology. Meaning that the present study should succesfully acquire diffuse and fluorescence spectra in breast , liver and lung tissue discriminating normal tissue from malignant tissue. | — |
Secondary
| Measure | Time frame |
|---|---|
| During the surgery procedure possibilities and inabilities of the measurement hardware will be recorded. Analysis of this documentation will provide information for possible alterations of hardware design for improved clinical applicability in the future. To evaluate whether spectroscopy can assess the completeness of tumor ablation, additional optical spectroscopy measurements will be performed before, during and after RFA ablation. | — |
Countries
Netherlands
Outcome results
None listed